Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	61.83	45.82	7.27	8.19	20.3
Short-Term Investments	78.57	14.4	-	4.93	-
Cash & Short-Term Investments	140.4	60.21	7.27	13.12	20.3
Cash Growth	133.17%	728.67%	-44.62%	-35.38%	21.31%
Other Current Assets	0.06	0.08	0.07	0.05	0.22
Total Current Assets	140.46	60.29	7.33	13.17	20.52
Net Property, Plant & Equipment	0.25	-	0.01	0.06	-
Total Assets	140.72	60.29	7.35	13.23	20.52
Accounts Payable	2.74	2.25	1.76	3.13	1.58
Accrued Expenses	-	3	-	-	-
Total Current Liabilities	2.74	5.25	1.76	3.13	1.58
Long-Term Leases	0.15	-	-	0.01	-
Total Long-Term Liabilities	0.15	-	-	0.01	-
Total Liabilities	2.89	5.25	1.76	3.14	1.58
Common Stock	0.01	0.01	0	0.01	0.01
Additional Paid-in Capital	227.2	130.79	65.81	61.87	60.22
Accumulated Other Comprehensive Income	0.13	0.04	-0.01	0.01	-0
Retained Earnings	-89.51	-75.79	-60.21	-51.8	-41.29
Shareholders' Equity	137.83	55.04	5.59	10.09	18.94
Total Liabilities & Equity	140.72	60.29	7.35	13.23	20.52
Total Debt	0.15	0	0	0.01	0
Net Cash (Debt)	140.24	60.21	7.27	13.11	20.3
Net Cash Growth	132.92%	728.67%	-44.58%	-35.43%	21.31%
Net Cash Per Share	18.92	15.89	2.63	5.16	8.14
Book Value	137.83	55.04	5.59	10.09	18.94
Book Value Per Share	18.60	14.52	2.02	3.97	7.59
Tangible Book Value	137.83	55.04	5.59	10.09	18.94
Tangible Book Value Per Share	18.60	14.52	2.02	3.97	7.59

Updated Mar 27, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q